Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.71 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | PTAFR | P25105 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | FABP3 | P05413 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10497960 | 0.89 | SMN1; SMN2 (0.92) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL3405063 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL416182 | 0.88 | SMN1; SMN2 (0.83) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL30665597 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL22982784 | 0.86 | FABP3 (0.71) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL12268499 | 0.86 | FABP3 (0.71) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL413349 | 0.85 | SMN1; SMN2 (0.91) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL2292290 | 0.84 | ADRA1D (0.81) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL417649 | 0.84 | SMN1; SMN2 (0.98) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D | |
| SCHEMBL30652294 | 0.84 | ADRA1D (0.81) | SMN1; SMN2NR5A2NR5A1MAPTADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | claimed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | claimed |
| US-20200376138-A1 | LIPID NANO PARTICLE COMPLEX COMPRISING APTIDE FUSED WITH CELL PENETRATING MATERIALS AND USE SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-12-03 | — | — | US | claimed |
| WO-2020241925-A1 | LIPID NANOPARTICLE COMPLEX CAPTURING APTIDE FUSED WITH CELL-PENETRATING MATERIAL AND USE THEREOF | 한국과학기술원 | 2020-12-03 | — | — | WO | claimed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | MODEX THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| EP-4562156-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Lonza Sales AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-20250161481-A1 | TARGETED LNP DELIVERY | MODEX THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025096824-A1 | TARGETED LNP DELIVERY | MODEX THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20130281409-A1 | Myelin Sheath Fatty Acids that Resolve Neuroinflammation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-20130119346-A1 | IRON PYRITE NANOCRYSTALS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2012088414-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120020878-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-01-26 | — | — | US | disclosed |
| US-20100311844-A1 | Spontaneously Forming Ellipsoidal Phospholipid Unilamellar Vesicles | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-09 | — | — | US | disclosed |
| EP-2081552-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | Children's Hospital Medical Center (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090142267-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2009-06-04 | — | — | US | disclosed |
| WO-2008051818-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161481-A1 | TARGETED LNP DELIVERY | CD4, LCP2, CD2 | SMN1; SMN2 1793/4885NR5A2 3461/4885NR5A1 4573/4885 |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | STAT6, STAT1, STAT5B | SMN1; SMN2 542/4885NR5A2 2931/4885NR5A1 3625/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | SMN1; SMN2 1150/4885NR5A2 2095/4885NR5A1 3094/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | SMN1; SMN2 1119/4885NR5A2 1807/4885NR5A1 1445/4885 |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | EXOSC5, EXOSC4, EXOSC10 | SMN1; SMN2 1847/4885NR5A2 4354/4885NR5A1 4277/4885 |
| US-20130281409-A1 | Myelin Sheath Fatty Acids that Resolve Neuroinflammation | MAG, FABP7, PMP22 | SMN1; SMN2 128/4885NR5A2 2874/4885NR5A1 3740/4885 |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | GPR68, LARP7, INCENP | SMN1; SMN2 958/4885NR5A2 1485/4885NR5A1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.